|1.||Kannagi, Reiji: 10 articles (05/2012 - 01/2004)|
|2.||Miyazaki, Keiko: 7 articles (05/2012 - 05/2004)|
|3.||Nanashima, A: 7 articles (03/2002 - 10/2000)|
|4.||Sawai, T: 7 articles (03/2002 - 10/2000)|
|5.||Nakagoe, T: 7 articles (03/2002 - 10/2000)|
|6.||Yamaguchi, H: 7 articles (03/2002 - 10/2000)|
|7.||Ayabe, H: 7 articles (03/2002 - 10/2000)|
|8.||Yasutake, T: 7 articles (03/2002 - 10/2000)|
|9.||Tsuji, T: 7 articles (03/2002 - 10/2000)|
|10.||Izawa, Mineko: 6 articles (05/2012 - 05/2004)|
05/01/2011 - "There are some typical changes; for example, sialyl-Lewis(a/x) glycoforms are more abundant in many types of cancers. "
08/01/2008 - "We developed a heterogeneous sandwich assay system to detect soluble CD44v specifically modified by the cancer-associated sialyl Lewis a/x glycotopes, using the extracellular domain of CD44v cleaved by the metalloproteinase ADAM10 as standard molecules. "
05/01/2007 - "Recent progress disclosed the presence of a normal counterpart of the determinant, namely disialyl Lewis a, which is predominantly expressed in non-malignant epithelial cells of the digestive organs, while sialyl Lewis a is preferentially expressed in cancers. "
07/01/2006 - "Sialyl Lewis A (SLe(a)), Lewis A (Le(a)), and Lewis B (Le(b)) have been studied in many different biological contexts, for example in microbial adhesion and cancer. "
10/01/2004 - "This result could be assumed to have been influenced by the difference in the metastatic preponderance in a high versus low sialyl Lewis(a) expression in the tumor cells. "
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
05/01/2015 - "The sialyl-Lewis A (sLeA) glycan forms the basis of the CA19-9 assay and is the current best biomarker for pancreatic cancer, but because it is not elevated in ∼25% of pancreatic cancers, it is not useful for early diagnosis. "
08/01/1996 - "Sialyl Lewis(a) ganglioside in pancreatic cancer tissue correlates with the serum CA 19-9 level."
05/01/2015 - "Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A."
04/30/1999 - "In gastrointestinal and pancreatic cancer cell lines, the amounts of beta3Gal-T5 transcripts were quite well correlated with the amounts of the sialyl Lewis a antigens. "
04/30/1999 - "The sialyl Lewis a antigen is a well known tumor marker, CA19-9, which is frequently elevated in the serum in gastrointestinal and pancreatic cancers. "
04/01/2013 - "We found that the β1,3 galactosyltransferase β3Gal-T5, responsible for sialyl-Lewis a synthesis, is dramatically reduced in colon adenocarcinomas, in terms of both transcript and enzyme activity levels. "
01/01/2002 - "High amounts of sialyl Lewis(a) are present in human adenocarcinomas of the colon, pancreas and stomach. "
05/14/1999 - "beta3GalTx activity is high in adenocarcinoma cells expressing sialyl-Lewis a and undetectable in all other cells, suggesting differential involvement and opposite regulation of such enzymes during carcinogenesis."
05/14/1999 - "Expression of beta3GalT1 transcript is high in normal colon mucosa and control neuroectodermal cells, which do not express sialyl-Lewis a antigen, and low in colon adenocarcinoma cells, as assessed by competitive RT-PCR. "
08/22/1996 - "Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen."
|4.||Neoplasm Metastasis (Metastasis)
12/01/2001 - "Significantly higher level of sialyl Lewis A was shown in the group of metastases than that of non-metastases (P < 0.0068. "
09/01/2001 - "Recent developments have suggested the important role of sialyl Lewis A and X in the step of hematogenous metastasis. "
12/01/1998 - "These findings suggest that some sialylglycoconjugates, perhaps sialyl Lewis A in particular, play an important role in the initial interaction of RAW117-H10 cells with the hepatic endothelium, leading to metastasis."
01/01/2014 - "Hepatitis B virus X protein specially regulates the sialyl lewis a synthesis among glycosylation events for metastasis."
12/01/2001 - "Paired elevation of E-selectin and sialyl Lewis A was significantly higher in the hematogenous metastases than non-metastases (P < 0.001, Fisher exact test). "
05/01/2002 - "E-selectin ligand Sialyl-Lewis a (SA-Le(a)) carbohydrate is expressed on many carcinomas. "
07/01/2000 - "The carbohydrate carcinoma antigens CA 125, DF3 and Sialyl Lewis(a) were detectable in some of the malignant and normal renal cells. "
06/20/1997 - "Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma."
03/03/1995 - "Cellular adhesion of sialyl-Lewis-a(SLea)-positive pancreas carcinoma to endothelial cells (EC) is augmented by activation of EC via up-regulated E-selectin expression on EC. "
07/30/1993 - "Importance of E-selectin (ELAM-1) and sialyl Lewis(a) in the adhesion of pancreatic carcinoma cells to activated endothelium."
|1.||5- acetylneuraminyl- (2- 3)- galactosyl- (1- 4)- (fucopyranosyl- (1- 3))- N- acetylglucosamine (sialyl Lewis x)
|4.||Complement System Proteins (Complement)
|2.||Heterologous Transplantation (Xenotransplantation)